하위메뉴바로가기
본문바로가기
HOME>Company>History

연혁

Company History 1966~2012

Company history 1960~1978

Company history 1969~1978
1969 Creation of Sunkyong Fibers Ltd.
1976 Listed on the Korean stock exchange,
Merged with Sunkyong Chemical Fibers Ltd.
1978 First developers of PET resins in Korea

Company history 1980~1989

Company history 1980~1989
1984 Establishment of R&D Centre
1985 Acquisition of a textile factory in Suwon
1987 Formation of SK CYTEC Ltd.
Acquisition of Samshin Pharma Ltd.
1988 Foundation of Sunbo Pharma Ltd.
Renamed to Sunkyong Industries Ltd.
1989 Construction of PTA/DMT plant Formation of Life Science R&D Centre
Development of PPS resins

Company history 1990~1999

Company history 1990~1999
1990 Creation of Petrochemical R&D Centre Renamed Sunkyong Pharmaceuticals Ltd.
1991 Creation of SK Keris Ltd.
in Indonesia Development of the ginkgo extract preparation, - Genexin®
1994 Development of the anti-arthritis patch,
Trast® and Development of polyester adhesives
1998 Renamed SK Chemicals Ltd.
Creation of SK NJC Ltd.
1999 Development of SUNPLA®,
Korea’s first new drug (a 3rd-generation platinum complex anti-cancer agent)
Exporting OMED® to EU.

Company history 2000~2009

Company history 2000~2009
2000 Formation of Huvis Ltd.
2001 Establishment of SK Chemicals Qingdao Ltd. in China
Development of the high-performance PETG resin, SKYGREEN®
2002 Development of Korea’s first natural drug,(JOINS®, an anti-arthritis agent)
Creation of SK Eurochem Ltd. in Poland.
2005 Establishment of SK Chemicals Suzhou Ltd. in China
Formation of SK Pharma Beijing Ltd. in China
Founding of SK Utis Ltd.
Merged SK Pharmaceuticals Ltd.
Creation of SK Petrochemical Ltd.
2006 Merged Dong Shin Pharma Ltd.
Development of biodiesel production technology
2007 Merged In2Gen.
Establishment of Ningbo SK Zhenbang Chemical Ltd.
Formation of SK Chemicals Pharma Beijing Ltd.
- Shanghai Branch.
Development of the anti-impotence drug, Mvix®.
2008 Founding of Guilin SK Zhongning Bio Ltd.
Creation of SK Chemicals GmbH in Germany.
Acquisition of UB Care, a healthcare solutions provider. Licensing SID530,
korea’s1st anti-cancer medicine, to Europe
2009 Formation of SK Syntec Ltd.
Creation of ST Green Energy Ltd. in Singapore
Development of environment-friendly transparent heat-resistant co-polyester ECOZEN®.
NBP601, Korea’s first bio-pharmaceutical drug is licensed.

2010년대

Company history 2010~
2010 ECOZEN® wins the Silver Prize in the “Korea Technology Awards “Top 10 New Korean Technologies”
Minister’s Award in “Bio Diesel National Green Technology Award”
SK NJC venture equity acquisition and merger,
Selected as the provider of vaccine production equipment for cell culture.
2011 Ecozen - Ground-breaking ceremony for the Andong Vaccine Plant.
EcoLab awarded the Eco-friendly Architecture Certification(LEED Platinum Certification) and Korean
Architecture Award
ECOZEN®, the world’s first eco-friendly heat-resistant transparent bio-copolyester – awarded US FDA
certification.
Awarded the Grand Prize(Green Management Division) in the Global Standard Management Awards.
Special CDP (Carbon Disclosure Project) Prize The launch of “Embix S®”, the world’s first film-type
anti-impotence drug.
2012 NBP601, a hemophilia treatment, is named one of Korea’s Ten New Technologies and wins the Minister
of Knowledge Economy Award
SID710, the patch-type dementia treatment Exelon, goes to EU
ell culture influenza vaccine received approval for first clinical trial by IND
2013 SK Chemicals and Teijin Chemicals launch joint venture INITZ and begin constructing PPS facilities
Andong Plant certified by LEED
PCT is named one of Korea’s Ten New Technologies and wins the Minister of Knowledge Economy Award
2014 Developed Sanofi Pasteur and the next generation’s pneumonia vaccine and concluded a supply contract
Acquired KGMP for L House
The Ansan plant is combined with S House. Initz concluded a contract for PPS supply and co-marketing.
Received the Grand Prize(Sustainable Management Division) in the Global Standard Management Awards
Acquired a permit for SKYCELLFLU®, Korea’s first cell-cultivated in#uenza vaccine, to come into the market Korea FDA
2015 Ranked First in the Chemicals Sector Listed Under DJSI Korea (2015)
Marketing Authorization Applications for NBP601 (Hemophilia Treatment) with the FDA (US) and EMA (EU)
Blood Derivatives Subsidiary 'SK Plasma' Established
World's First in Marketing Authorization for Cell-Culture Flu Vaccine
SKYCellflu® Launched, South Korea's First Cell-Culture Flu Vaccine
2016 Dongtan Molding Lab Relocated and Expanded
Korea's First High-Performance Secondary Battery Electrolyte Additive Developed
DMT Production Facilities Expanded (Cap-up)
SKYCellflu Quadrivalent Launched, World's First Quadrivalent Cell-Culture Flu Vaccine
First Ever Marketing Authorization in US/Canada for Afstyla, a New Korean Antihemophilic Bio Drug